KPV: what is studied, gut and skin
Each study named, with its model: cell, mouse or human.
KPV has been studied for gut inflammation in mouse colitis models and for skin inflammation in a mouse model and in human skin cells in the lab. We found no published study of KPV’s effects in people. That is research, not an established benefit. KPV is not FDA-approved, and REMEVi does not currently offer it.
KPV is not FDA-approved. Since HHS’s October 2026 interim policy, a state-licensed 503A pharmacy may compound it on a patient-specific prescription under listed conditions.
REMEVi does not currently offer KPV.
Gut research: colitis models
| Study | Model | What was measured |
|---|---|---|
| Dalmasso et al., Gastroenterology 2008 | Human intestinal and immune cell lines; mice with DSS- or TNBS-induced colitis (oral KPV in drinking water) | Uptake through the PepT1 transporter; inflammatory signaling (NF-κB, MAP kinase); cytokines; colitis in mice |
| Kannengiesser et al., Inflammatory Bowel Diseases 2008 | Mice: DSS colitis and T-cell transfer colitis, including mice lacking a working melanocortin-1 receptor | Body weight, tissue inflammation, myeloperoxidase activity, survival |
| Xiao et al., Molecular Therapy 2017 | Mice with DSS colitis, KPV in hyaluronic-acid nanoparticles by oral gavage | Body weight, colon length, myeloperoxidase activity, TNF-α, tissue findings |
In these mouse studies, the authors reported lower inflammation measures in KPV-treated animals than in controls. Mouse colitis is induced by chemicals or by transferred immune cells; it is a model, not inflammatory bowel disease in a person, and results in mice often do not hold in humans.
Skin research
| Study | Model | What was measured |
|---|---|---|
| Hiltz & Lipton, FASEB Journal 1989 | Mice: chemically induced ear swelling (contact dermatitis model) | Ear swelling with the alpha-MSH 11–13 fragment, compared with saline and a corticosteroid |
| Elliott et al., Journal of Investigative Dermatology 2004 | Human keratinocytes in the lab (a cell line and normal cells) | Cell signaling: cyclic AMP and calcium responses to KPV |
| Böhm & Luger, Experimental Dermatology 2019 | Review article, not a new experiment | Discusses KPV-like peptides as candidates for wound research; reports no human KPV trial in its abstract |
Skin research on KPV is earlier and thinner than the gut work: one mouse inflammation model, lab experiments on human skin cells, and reviews. None tested topical KPV on people’s skin conditions.
What has been studied in people
Nothing published that we could find. Human cells have been studied in the lab, but no trial has reported what KPV does when people take it by mouth or apply it to skin (PubMed, checked November 2, 2026). So any “KPV benefits” list rests on cell and mouse data.
Does KPV work for gut inflammation?
That is not known in people. KPV has been studied in mouse colitis models, where researchers reported lower inflammation measures, and in human intestinal cells in the lab. No published human trial has tested KPV for gut inflammation, so mouse results cannot tell anyone what KPV would do for them.
Is KPV good for skin?
There is no human evidence either way. KPV’s skin research is a 1989 mouse ear-swelling model and lab work on human skin cells. Topical KPV is a route HHS’s 2026 policy lists, but that is a compounding rule, not evidence of an effect. A licensed provider can discuss skin options that have human data.
Sources
- Dalmasso et al., Gastroenterology 2008 — PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (read November 2, 2026)
- Kannengiesser et al., Inflammatory Bowel Diseases 2008 — Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease (read November 2, 2026)
- Xiao et al., Molecular Therapy 2017 — Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis (read November 2, 2026)
- Hiltz & Lipton, FASEB Journal 1989 — Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH (read November 2, 2026)
- Elliott et al., Journal of Investigative Dermatology 2004 — Alpha-melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells (read November 2, 2026)
- Böhm & Luger, Experimental Dermatology 2019 — Are melanocortin peptides future therapeutics for cutaneous wound healing? (review) (read November 2, 2026)
- HHS, Federal Register — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (91 FR 68526, October 30, 2026) (read November 2, 2026)
Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·